News

Published on 6 Oct 2022 on Zacks via Yahoo Finance

Is ChemoCentryx (CCXI) Stock Outpacing Its Medical Peers This Year?


Article preview image

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has ChemoCentryx (CCXI) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.

ChemoCentryx is a member of our Medical group, which includes 1193 different companies and currently sits at #5 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.

The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. ChemoCentryx is currently sporting a Zacks Rank of #2 (Buy).

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Is ChemoCentryx (CCXI) Stock Outpacing Its Medical Peers This Year?

For those looking to find strong Medical stocks, it is prudent to search for companies in the gro...

Zacks via Yahoo Finance 6 Oct 2022

Why Is ChemoCentryx (CCXI) Up 1.4% Since Last Earnings Report?

A month has gone by since the last earnings report for ChemoCentryx (CCXI). Shares have added abo...

Zacks via Yahoo Finance 7 Sep 2022

How Covid, 'industrial logic' and a threat played out in a multibillion-dollar biotech merger

Amgen Inc.'s persistence and patience won out in a 29-month saga that landed it a Peninsula compa...

American City Business Journals 1 Sep 2022

Aerie (AERI) Rallies 205.6% in the Past Three Months: Here's Why

Shares of Aerie Pharmaceuticals AERI have skyrocketed in the past three months, outpacing other m...

Zacks via Yahoo Finance 31 Aug 2022

Top Analyst Reports for Alphabet, Goldman Sachs & Anheuser-Busch

Wednesday, August 31, 2022 The Zacks Research Daily presents the best research output of our anal...

Zacks via Yahoo Finance 31 Aug 2022

Amgen (AMGN) Outperforms Industry Year to Date: What's Next?

Amgen AMGN has a diverse and growing portfolio of medicines in large therapeutic categories that ...

Zacks via Yahoo Finance 30 Aug 2022

What Biotech ETFs Might Be Right for Your Portfolio?

ETFS Biotech is back. For those who want to invest through exchange-traded funds, here are some c...

The Wall Street Journal 19 Aug 2022

ChemoCentryx (CCXI) Now Trades Above Golden Cross: Time to Buy?

After reaching an important support level, ChemoCentryx, Inc. (CCXI) could be a good stock pick f...

Zacks via Yahoo Finance 16 Aug 2022

Here's Why ChemoCentryx (CCXI) is a Great Momentum Stock to Buy

Momentum investing is all about the idea of following a stock's recent trend, which can be in eit...

Zacks via Yahoo Finance 16 Aug 2022

The Zacks Analyst Blog Highlights Amgen, ChemoCentryx, Mersana Therapeutics, GSK and Vertex...

For Immediate Release Chicago, IL – August 12, 2022 – Zacks.com announces the list of stocks feat...

Zacks via Yahoo Finance 12 Aug 2022